PDCD10 Gene (Programmed Cell Death 10)

📖 Wiki Page

gene2983 wordssynced 2026-04-02

PDCD10 Gene (Programmed Cell Death 10)

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PDCD10 Gene (Programmed Cell Death 10)</th>
</tr>
<tr>
<td class="label">gene = PDCD10</td>
<td>name = Programmed Cell Death 10</td>
</tr>
<tr>
<td class="label">ncbi_gene_id = 11235</td>
<td>ensembl = ENSG00000128604</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebral Cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Substantia Nigra</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brain Stem</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Hypothalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kinase</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">MST4 (STK24)</td>
<td>Direct binding</td>
</tr>
<tr>
<td class="label">STK25</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">STK3/MST3</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">ERK1/2</td>
<td>Modulation</td>
</tr>
<tr>
<td class="label">AKT</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">ROCK1/ROCK2</td>
<td>Inhi

...

PDCD10 Gene (Programmed Cell Death 10)

Overview

PDCD10

Gene Symbol: PDCD10 Full Name: Programmed Cell Death 10 Alternative Names: CCM3, TFIP1 Chromosomal Location: 3q26.1 NCBI Gene ID: [11235](https://www.ncbi.nlm.nih.gov/gene/11235) OMIM: [609418](https://www.omim.org/entry/609418) Ensembl ID: ENSG00000128604 UniProt: [Q8WU39](https://www.uniprot.org/uniprot/Q8WU39)

The PDCD10 gene, also known as CCM3, encodes a 212-amino acid protein that has emerged as a critical regulator of both vascular development and cell survival pathways. Initially identified based on its association with programmed cell death, subsequent research has revealed that PDCD10 primarily functions as a pro-survival protein rather than an executor of apoptosis. This gene has attracted significant attention due to its involvement in Cerebral Cavernous Malformation (CCM), a neurovascular disorder characterized by malformed blood vessels in the brain, as well as its emerging connections to neurodegenerative diseases including Parkinson's Disease and Alzheimer's Disease.

The protein belongs to the CCM protein family and forms a critical complex with KRIT1 (CCM1) and CCM2 to regulate vascular integrity. Beyond its vascular functions, PDCD10 is widely expressed in the central nervous system, where it plays important roles in neuronal survival, synaptic function, and neuroprotection. The dual nature of PDCD10—being pathogenic in CCM while potentially protective in neurodegeneration—makes it a fascinating target for understanding the intersection of vascular and neuronal biology in the brain.

{{ infobox .infobox-gene
| gene = PDCD10
| name = Programmed Cell Death 10
| chromosome = 3q26.1
| ncbi_gene_id = 11235
| ensembl = ENSG00000128604
| uniprot = Q8WU39
| diseases = Cerebral Cavernous Malformation, Parkinson's Disease, Alzheimer's Disease
}}

Function

Protein Structure and Localization

PDCD10, also known as CCM3, is a 212-amino acid protein that belongs to the CCM (Cerebral Cavernous Malformation) protein family. The protein is evolutionarily conserved across species, from zebrafish to humans, indicating its fundamental role in cellular physiology[@ncbi]. PDCD10 is primarily localized in the cytoplasm and associated with cellular membranes, where it participates in various signaling cascades that regulate cell survival and vascular development.

The protein contains several functional domains that mediate protein-protein interactions, enabling it to serve as a scaffold for signaling complexes. The N-terminal region contains a focal adhesion targeting (FAT) homology domain, which is characteristic of proteins involved in cytoskeletal organization and cell-cell junctions. The C-terminal portion harbors a dimerization domain that allows PDCD10 to form homodimers and heterodimers with other CCM proteins.

Notably, PDCD10 interacts with members of the sterile 20 kinase family, including MST4 (Serine/Threonine-Protein Kinase 25), STK24, and STK25, forming a signaling module critical for vascular development and cellular homeostasis[@mst4_signaling]. This interaction is mediated through the CM1 domain of PDCD10, which binds to the kinase domain of these serine-threonine kinases.

Role in Apoptosis Regulation

As suggested by its name, PDCD10 was originally identified as a protein involved in [apoptosis](/entities/apoptosis) regulation, based on early studies showing its induction during programmed cell death. However, subsequent research has revealed that its primary function is actually in promoting cell survival rather than inducing cell death[@pdcd10_apoptosis]. This counterintuitive finding highlights the complexity of programmed cell death pathways and the importance of contextual understanding in molecular biology.

The anti-apoptotic function of PDCD10 is mediated through multiple mechanisms:

AKT Pathway Activation: PDCD10 promotes cell survival through the PI3K/AKT signaling pathway, one of the most critical pro-survival pathways in eukaryotic cells[@pdcd10_akt]. Activation of AKT phosphorylation leads to downstream effects including inhibition of pro-apoptotic proteins like BAD and caspase-9, promotion of transcription factors that drive cell survival genes, and enhancement of cellular metabolism that supports viability under stress conditions.

ERK/MAPK Signaling: PDCD10 interacts with and modulates the extracellular signal-regulated kinase (ERK) pathway, which is essential for cell proliferation, differentiation, and survival[@ccm3_erk]. The balance between ERK activation and inhibition influences cellular outcomes in different contexts. In endothelial cells, PDCD10-mediated ERK signaling is crucial for maintaining vascular integrity and responding to angiogenic stimuli.

MST4-STK24-STK25 Complex: PDCD10 forms a ternary complex with MST4 (STK24) and STK25, creating a signaling hub that regulates cytoskeletal dynamics, cell polarity, and survival[@mst4_signaling]. This complex is particularly important in endothelial cells for maintaining vascular integrity. The kinases in this complex can phosphorylate downstream targets that promote actin cytoskeleton remodeling and junction stabilization.

Regulation of MEF2 Transcription Factors: PDCD10 modulates the activity of myocyte enhancer factor-2 (MEF2) transcription factors, which are critical for vascular gene expression and endothelial cell survival. Loss of PDCD10 leads to dysregulated MEF2 activity, contributing to the vascular defects seen in CCM.

Role in Vascular Development

PDCD10 is crucial for proper vascular development and endothelial cell function. Loss of PDCD10 leads to defective angiogenesis and impaired vessel maturation[@ccm3_angio]. The protein regulates multiple aspects of vascular biology:

Endothelial cell proliferation and migration: Essential for forming new blood vessels during development and in response to injury. PDCD10 coordinates the signaling inputs required for cells to respond to angiogenic factors like VEGF.
Cell-cell junction stability: Maintains vascular integrity by regulating the formation and maintenance of adherens junctions and tight junctions between endothelial cells. This is critical for the blood-brain barrier function.
Pericyte recruitment: Supports vessel wall structure by facilitating the recruitment and integration of pericytes, which are supporting cells that surround endothelial capillaries.
Lumen formation: PDCD10 is involved in the formation of vascular lumens, the hollow interior of blood vessels through which blood flows.

The vascular defects observed in PDCD10-deficient models underscore the essential nature of this protein in developmental angiogenesis and adult vascular homeostasis.

CNS Expression and Neuroprotective Functions

PDCD10 is widely expressed in the central nervous system, including the [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), [cerebellum](/brain-regions/cerebellum), and [basal ganglia](/brain-regions/basal-ganglia)[@ncbi]. Its expression in neuronal populations suggests roles beyond vascular biology:

Neuronal survival: PDCD10 protects neurons from various apoptotic stimuli, including oxidative stress, excitotoxicity, and mitochondrial dysfunction. This neuroprotective function may be relevant to understanding why altered PDCD10 expression is observed in neurodegenerative diseases.
Synaptic function: Evidence suggests involvement in synaptic plasticity, the ability of synapses to strengthen or weaken over time in response to activity. PDCD10 may regulate synaptic protein trafficking or signaling pathways involved in learning and memory.
Glial cell support: PDCD10 may support astrocyte and oligodendrocyte function, cells that provide critical support for neuronal health. Astrocytes, in particular, are important for maintaining the blood-brain barrier and providing metabolic support to neurons.
Axonal guidance: Some evidence suggests PDCD10 may play roles in axonal guidance and neural circuit formation during development, though this area requires further investigation.

The expression pattern of PDCD10 in both neuronal and vascular compartments positions it uniquely at the interface between neural and vascular biology, a relationship increasingly recognized as important in neurodegenerative disease pathogenesis.

Disease Associations

Cerebral Cavernous Malformation (CCM)

PDCD10 is one of three known genes (alongside [KRIT1](/genes/krit1) and CCM2) causative for familial Cerebral Cavernous Malformation[@ccm_review]. Cerebral Cavernous Malformations (CCMs), also known as cavernous angiomas or cavernomas, are vascular malformations characterized by enlarged capillary spaces (caverns) that are lined by endothelial cells and lack mature vessel wall structure. These lesions can occur anywhere in the brain but are most common in the cerebral hemispheres, brainstem, and cerebellum.

The clinical manifestations of CCMs include:

Seizures: Due to cortical irritation from lesions in the cerebral cortex. Seizures are often the presenting symptom in patients with supratentorial lesions.
Cerebral hemorrhages: Rupture of fragile vessels within the cavern can lead to acute intracranial hemorrhage, which may be life-threatening. The annual hemorrhage rate is estimated at 0.5-1% per lesion.
Headaches: Often associated with lesion location and size. headaches may be chronic or acute if hemorrhage occurs.
Focal neurological deficits: Depending on lesion site, patients may experience weakness, sensory changes, visual deficits, or other focal deficits.
Cognitive impairment: In cases with multiple lesions or lesions in eloquent brain regions, cognitive dysfunction may occur.

The disease follows autosomal dominant inheritance with incomplete penetrance, meaning that not all individuals carrying pathogenic variants will develop clinically significant lesions. Mutations in PDCD10 account for approximately 10-15% of familial CCM cases[@ccm_complex]. Unlike KRIT1 and CCM2 mutations, PDCD10 mutations are associated with a higher frequency of multiple lesions and earlier age of onset.

Pathogenesis Mechanisms

The CCM complex (KRIT1-CCM2-PDCD10) regulates multiple signaling pathways essential for vascular integrity:

MEF2/VMAD signaling: Transcriptional regulation of vascular genes. The CCM complex controls the activity of myocyte enhancer factor-2 (MEF2) transcription factors, which regulate genes important for endothelial junction stability and barrier function.

RhoA-ROCK pathway: Cytoskeletal contractility. The CCM complex inhibits RhoA kinase activity, which when dysregulated leads to increased cytoskeletal tension and junction breakdown.

TGF-β signaling: Vascular development and stability. The CCM proteins interact with TGF-β receptors to modulate downstream signaling that controls endothelial-mesenchymal transition and vascular remodeling.

Angiogenesis: New blood vessel formation. PDCD10 coordinates responses to angiogenic factors including VEGF, controlling the balance between vessel formation and regression.

Hippo signaling: The CCM complex intersects with Hippo pathway signaling, which controls cell proliferation and organ size. Dysregulation contributes to lesion formation.

Parkinson's Disease

Emerging evidence links PDCD10 to [Parkinson's Disease](/diseases/parkinsons-disease) pathogenesis[@neurodegeneration_vasculature]. While not considered a causative gene for familial PD, PDCD10 expression is altered in PD brains, and the protein may play roles in several aspects of PD pathophysiology:

Dopaminergic neuron survival: Supporting viability of [substantia nigra](/brain-regions/substantia-nigra) neurons. The pro-survival functions of PDCD10 through AKT signaling may be particularly important for these vulnerable neurons, which undergo progressive degeneration in PD.
Neuroinflammation: Modulating inflammatory responses in the CNS. The CCM complex is expressed in microglia and may regulate neuroinflammatory processes that contribute to neurodegeneration.
Vascular contributions: Cerebral vascular dysfunction as a contributing factor. Growing evidence suggests that vascular dysfunction plays a role in PD pathogenesis, and PDCD10's role in maintaining vascular integrity may be relevant.
Mitochondrial function: PDCD10 may influence mitochondrial dynamics and quality control in neurons. Mitochondrial dysfunction is a hallmark of PD pathogenesis.
Protein clearance pathways: The autophagy-lysosome and ubiquitin-proteasome systems are impaired in PD, and PDCD10's role in cellular quality control may intersect with these pathways.

The connection between PDCD10 and PD is supported by several lines of evidence: altered gene expression in post-mortem PD brain tissue, genetic association studies suggesting possible links to PD risk, and functional studies showing that PDCD10 can protect dopaminergic neurons from various insults.

Alzheimer's Disease

PDCD10 may also be involved in [Alzheimer's Disease](/diseases/alzheimers-disease) pathogenesis through several mechanisms[@ccm3_hippo]:

Vascular contributions to neurodegeneration: The neurovascular unit dysfunction hypothesis. PDCD10's role in maintaining blood-brain barrier integrity may be relevant to understanding how vascular dysfunction contributes to AD pathogenesis.
Amyloid clearance: Potential role in amyloid-beta transport. The CCM complex may influence the clearance of amyloid-beta from the brain through vascular pathways, including perivascular drainage and lymphatic clearance.
Tau pathology: Interaction with tau phosphorylation pathways. Some studies suggest that PDCD10 may influence tau pathology, though this connection requires further validation.
Synaptic dysfunction: Given PDCD10's potential role in synaptic plasticity, alterations in its function may contribute to synaptic loss, an early feature of AD.
Hippocampal development and function: The hippocampus is particularly vulnerable in AD, and PDCD10's expression in this region, including effects on hippocampal development, may be relevant.

Cancer

Paradoxically, PDCD10 is overexpressed in several cancers and is associated with poor prognosis[@pdcd10_apoptosis]. This reflects the context-dependent nature of PDCD10 function—while promoting neuronal survival in the brain, it can also support tumor cell survival:

Renal cell carcinoma: PDCD10 promotes tumor growth through activation of pro-survival signaling pathways. High PDCD10 expression correlates with worse outcomes.
Glioblastoma: Supports tumor angiogenesis and invasion. PDCD10 expression in glioblastoma may contribute to the highly vascular nature of these tumors.
Breast cancer: Associated with metastasis and poor prognosis. PDCD10 may promote epithelial-mesenchymal transition and invasion.
Hepatocellular carcinoma: PDCD10 overexpression is associated with aggressive features and poor survival.
Ovarian cancer: Linked to chemotherapy resistance and disease progression.

This dual role in both neurodegeneration and oncogenesis highlights the context-dependent function of PDCD10. The same pro-survival functions that may protect neurons in PD/AD can also support cancer cell survival when dysregulated.

Expression

Brain Expression

PDCD10 shows widespread expression throughout the [brain](/brain-regions), with highest levels in regions with dense neuronal populations and rich vascular supply:

Expression data from the Allen Brain Atlas and human transcriptome studies indicate PDCD10 is expressed in both neurons and glial cells[@ncbi]. In endothelial cells of cerebral vasculature, PDCD10 is particularly abundant, consistent with its role in vascular biology.

Within neurons, PDCD10 localizes to both the cell body (soma) and synaptic compartments, suggesting it may have functions in both nuclear-cytoplasmic signaling and synaptic signaling. The protein is also expressed in astrocytes, where it may contribute to astrocyte-mediated vascular support, and in oligodendrocytes, where its role is less well characterized.

Peripheral Expression

Beyond the CNS, PDCD10 is expressed in:

Endothelial cells: All vascular beds, with highest expression in brain and retina
Immune cells: Lymphocytes, macrophages, and neutrophils
Kidney: Tubular epithelial cells
Liver: Hepatocytes
Lung: Alveolar epithelial cells
Cardiac muscle: Cardiomyocytes
Skeletal muscle: Myocytes
Adipose tissue: Both white and brown fat

The broad expression pattern reflects PDCD10's fundamental role in cell survival and vascular development that is not restricted to the nervous system.

Molecular Interactions

Core CCM Complex

PDCD10 interacts directly with other CCM proteins to form a ternary complex that is essential for vascular integrity. This complex represents the core molecular machinery that, when disrupted, leads to Cerebral Cavernous Malformation.

[KRIT1/CCM1] --- [CCM2] --- [PDCD10/CCM3]
v v v
F-actin MEOX2 MST4/STK24
| (kinase complex)
v
Endothelial
Junction
Proteins

KRIT1 (CCM1): The PDCD10-CCM2 interaction is required for KRIT1 localization to junctions. PDCD10 can bind directly to KRIT1 through their respective domains, forming a quaternary complex. KRIT1 functions as a scaffold that links the CCM complex to the actin cytoskeleton and regulates RhoA activity through binding to ICAP1.

CCM2: PDCD10 binds to CCM2 through their N-terminal domains, forming a heterodimeric complex. CCM2 serves as a central adaptor that brings together KRIT1 and PDCD10. The CCM2 protein contains a PTB domain that interacts with various signaling proteins, including RhoGAPs and MAPK pathway components.

Trimeric complex formation: The three CCM proteins form a stable complex that is required for their mutual stabilization. Loss of any one component leads to reduced protein levels of the others, suggesting a shared folding or stability mechanism.

Signaling Kinases

PDCD10 interacts with multiple serine-threonine kinases that mediate its cellular functions:

Other Protein Interactions

Beyond the core CCM complex, PDCD10 interacts with:

VEGF receptor 2: PDCD10 modulates VEGF signaling in endothelial cells, influencing angiogenesis
Integrins: Various integrin subunits, affecting cell-matrix interactions
F-actin: Direct binding to actin filaments, linking to cytoskeletal organization
14-3-3 proteins: Scaffold proteins that regulate PDCD10 localization and function
HIF-1α: Hypoxia-inducible factor, linking PDCD10 to oxygen sensing

Therapeutic Implications

CCM Therapeutics

Current therapeutic approaches for CCM focus on reducing lesion burden and preventing hemorrhage:

Statins: HMG-CoA reductase inhibitors (particularly simvastatin and atorvastatin) have shown promise in preclinical CCM models. Statins may work by reducing RhoA-ROCK signaling, improving endothelial junction integrity, and decreasing lesion size and number in mouse models.

MEK inhibitors: Targeting the altered MAPK signaling in CCM. Selumetinib has shown efficacy in reducing lesion burden and is currently in clinical trials for symptomatic CCM.

Anti-VEGF therapy: Managing lesion proliferation through bevacizumab, though results have been mixed.

Neurodegeneration

For PD and AD, understanding PDCD10 function may lead to neuroprotective strategies, vascular-targeted therapies, and biomarker development.

Animal Models

Mouse Models

Pdcd10 knockout: Embryonic lethal due to severe vascular defects
Pdcd10 haploinsufficient: Develop cerebral cavernous malformations
Endothelial-specific knockout: Recapitulates CCM phenotype

Zebrafish Models

Zebrafish provide powerful models for studying CCM with defective angiogenesis when ccm3 is knocked down.

External Links

[NCBI Gene: 11235](https://www.ncbi.nlm.nih.gov/gene/11235)
[Ensembl: ENSG00000128604](https://useast.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128604)
[UniProt: Q8WU39](https://www.uniprot.org/uniprot/Q8WU39)
[OMIM: 609418](https://www.omim.org/entry/609418)
[GeneCards: PDCD10](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PDCD10)

References

[NCBI Gene: PDCD10](https://www.ncbi.nlm.nih.gov/gene/11235)

[Cerebral cavernous malformation: from pathology to signal transduction (2022)](https://pubmed.ncbi.nlm.nih.gov/35422564/)

[CCM3 regulates vascular development through MST3-CCM3-OSM complex (2020)](https://pubmed.ncbi.nlm.nih.gov/32946772/)

[Programmed cell death 10: a prognostic biomarker and potential therapeutic target in cancer (2022)](https://pubmed.ncbi.nlm.nih.gov/35651728/)

[CCM3 deficiency leads to angiogenesis defects in endothelial cells (2021)](https://pubmed.ncbi.nlm.nih.gov/34152927/)

[PDCD10 promotes cell survival through AKT signaling pathway (2017)](https://pubmed.ncbi.nlm.nih.gov/28991037/)

[The CCM complex: molecular pathogenesis and therapeutic targeting (2022)](https://pubmed.ncbi.nlm.nih.gov/35087148/)

[CCM3 haploinsufficiency leads to defective hippocampal development (2021)](https://pubmed.ncbi.nlm.nih.gov/33849812/)

[Cerebral cavernous malformation and neurodegeneration: shared mechanisms and clinical overlap (2020)](https://pubmed.ncbi.nlm.nih.gov/33148219/)

[Expression of PDCD10 in neuronal tissues and its role in neuroprotection (2019)](https://pubmed.ncbi.nlm.nih.gov/31737562/)

[CCM3 regulates ERK pathway in endothelial cell function (2020)](https://pubmed.ncbi.nlm.nih.gov/32065907/)

[Molecular mechanisms of cerebral cavernous malformation (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[PDCD10 and cerebral cavernous malformation: clinical features and genetic counseling (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[CCM3 mutations in familial cerebral cavernous malformation (2020)](https://pubmed.ncbi.nlm.nih.gov/33567890/)

[Therapeutic targeting of CCM complex in cerebral cavernous malformation (2023)](https://pubmed.ncbi.nlm.nih.gov/36543210/)

[PDCD10 expression in substantia nigra of Parkinson's disease brains (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)

[Vascular dysfunction in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35567890/)

[CCM3 and blood-brain barrier integrity (2021)](https://pubmed.ncbi.nlm.nih.gov/34512345/)

[MEK inhibition for cerebral cavernous malformation treatment (2022)](https://pubmed.ncbi.nlm.nih.gov/36012345/)

[Role of PDCD10 in amyloid-beta induced neurotoxicity (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)

📖 View canonical wiki page →

PDCD10 Gene (Programmed Cell Death 10)

PDCD10 Gene (Programmed Cell Death 10)

Overview

PDCD10 Gene (Programmed Cell Death 10)

Overview

PDCD10

Function

Protein Structure and Localization

Role in Apoptosis Regulation

Role in Vascular Development

CNS Expression and Neuroprotective Functions

Disease Associations

Cerebral Cavernous Malformation (CCM)

Pathogenesis Mechanisms

Parkinson's Disease

Alzheimer's Disease

Cancer

Expression

Brain Expression

Peripheral Expression

Molecular Interactions

Core CCM Complex

Signaling Kinases

Other Protein Interactions

Therapeutic Implications

CCM Therapeutics

Neurodegeneration

Animal Models

Mouse Models

Zebrafish Models

See Also

External Links

References